Lebovits Chaim 4

What Happened

• Chaim Lebovits, President & CEO of Brainstorm Cell Therapeutics (BCLI), received a grant of 1,800,000 restricted stock units (RSUs) on 2026-02-26. The award is reported at $0 per share (an equity compensation grant, not a market purchase). Under the award terms, 50% of the RSUs vested on the grant date and the remaining 50% vests on the six-month anniversary, subject to continued employment.

Key Details

• Transaction type: Award/Grant (RSUs)
• Transaction date: 2026-02-26; Filing date: 2026-05-29 (filed ~92 days after the transaction — late filing)
• Shares/units granted: 1,800,000 RSUs at $0.00
• Vesting: 50% vested on grant date; remaining 50% vests six months later, conditioned on continued employment (per footnote)
• Shares owned after transaction: Not specified in the filing
• No 10b5-1 plan, tax withholding, or sale reported in this filing

Context

• RSU grants are a common form of executive compensation and are different from open‑market purchases or sales; half of this award vested immediately (providing immediate equity) while the remainder is time‑based. Because this was an award (not a purchase), it should be viewed as compensation disclosure rather than a direct market-confidence signal. Note the filing was submitted significantly after the transaction date, which affects public timeliness of the disclosure.